Wedbush Estimates AnaptysBio’s FY2024 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Wedbush raised their FY2024 earnings per share estimates for shares of AnaptysBio in a research note issued to investors on Tuesday, November 5th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings of ($5.22) per share for the year, up from their previous forecast of ($6.65). Wedbush currently has a “Outperform” rating and a $42.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.84) per share. Wedbush also issued estimates for AnaptysBio’s Q4 2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($3.53) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%.

A number of other analysts have also recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. UBS Group lifted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. HC Wainwright decreased their price objective on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday. Guggenheim raised their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.45.

AnaptysBio Stock Down 3.2 %

Shares of ANAB stock opened at $21.49 on Friday. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $41.31. The firm’s 50-day moving average is $33.00 and its 200-day moving average is $29.83.

Institutional Trading of AnaptysBio

Several large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio during the first quarter valued at approximately $38,000. Values First Advisors Inc. bought a new position in shares of AnaptysBio in the 3rd quarter valued at $49,000. nVerses Capital LLC raised its holdings in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after buying an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares in the last quarter.

Insider Buying and Selling at AnaptysBio

In related news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of AnaptysBio stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was purchased at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now directly owns 7,794,996 shares in the company, valued at approximately $284,517,354. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 in the last quarter. Company insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.